Compare Ishares Msci Brazil ETF (EWZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Merck & Co., Inc. — how do they compare? Ishares Msci Brazil ETF trades at $33.95, while Merck & Co., Inc. trades at $133.05 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Ishares Msci Brazil ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| EWZ | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $131.84 |
52-Week Low | $27.36 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $33.94, down 3.55% today, with a bearish technical signal driven by moving averages. The ETF faces headwinds from US tariffs on Brazilian goods and mixed sentiment, though oscillators suggest potential near-term support. A dividend of $0.33 is scheduled for June 2026, while institutional investors like Empowered Funds LLC have recently increased positions, indicating some confidence in Brazilian equity value.
The outlook for EWZ hinges on Brazil's economic policies and commodity markets, offering exposure to emerging market growth but with volatility risks from trade tensions and currency fluctuations. Investors should weigh the ETF's high expense ratio against alternatives like FLBR, which offers lower costs and higher dividends, as noted in recent analyst comparisons.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
